Propiram

Overview

Propiram (Algeril, Dirame, Bay 4503) is a partial μ-opioid receptor agonist and weak μ antagonist analgesic from the ampromide family of drugs related to other drugs such as phenampromide and diampromide. It was invented in 1963 in the United Kingdom by Bayer but was not widely marketed, although it saw some limited clinical use, especially in dentistry. Propiram reached Phase III clinical trials in the United States and Canada.[1][2][3] WP

Pharmacology

Pharmacology

Propiram exhibits weak opioid antagonist activity on the μ receptor—quite a bit weaker than its agonist effects—and the effect on κ- and δ-opioid, σ-receptors, or the NMDA system are not well understood. Other drugs of the partial μ-opioid agonist/antagonist type include meptazinol, buprenorphine, butorphanol, phenazocine, nalbuphine, pentazocine, dezocine and its relatives. WP

With about 10% of the analgesic potency of morphine, 50 mg of propiram is equivalent to about 60 mg of codeine or 50 mg of pentazocine. In many patients, propiram is an effective analgesic comparable to other drugs such as these as well as pethidine, with a normal dose of around 50–100 mg and a duration of action of 3 to 6 hours. It is more potent and effective than codeine, and longer-lasting and with a faster onset of action compared to pethidine. Side effects include sedation, dizziness, nausea and vomiting. Propiram has been available in oral, rectal, and injectable formulations, with bioavailability above 97% after oral administration.[4–7] WP

Legal status

Regulation

Propiram is currently a Schedule I/Narcotic controlled substance in the United States with an ACSCN of 9649 and a zero annual aggregate manufacturing quota as of 2014. It has been almost exclusively formulated as the fumarate salt. WP

Chemistry

Formula

C16H25N3O PC

CAS number

15686-91-6 PC

Molar mass (g/mol)

275.39 PC

IUPAC name (computed by PubChem)

N-(1-piperidin-1-ylpropan-2-yl)-N-pyridin-2-ylpropanamide PC

SMILES

CCC(=O)N(C1=CC=CC=N1)C(C)CN2CCCCC2 PC

InChIKey

ZBAFFZBKCMWUHM-UHFFFAOYSA-N PC

PubChem CID

26216

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Other US3163654A Pyridine derivatives and their preparation (n-tertiary aminoalkyl-n-acyl)-amino pyridines
2. Other U.S. patent 3163654
3. Other Drug Facts & Comparisons. 2002
4. Journal / agency Wilson RS, Landers JH. Use of a new oral analgesic, propiram fumarate, in treating postoperative ocular pain. Annals of Ophthalmology. December 1982. PMID 7165237
5. Journal / agency Desjardins PJ, Cooper SA, Gallegos TL, Allwein JB, Reynolds DC, Kruger GO, Beaver WT. The relative analgesic efficacy of propiram fumarate, codeine, aspirin, and placebo in post-impaction dental pain. Journal of Clinical Pharmacology. January 1984. doi:10.1002/j.1552-4604.1984.tb01811.x · PMID 6368614
6. Journal / agency Korduba CA, Veals J, Radwanski E, Symchowicz S, Chung M. Bioavailability of orally administered propiram fumarate in humans. Journal of Pharmaceutical Sciences. May 1981. doi:10.1002/jps.2600700515 · PMID 7241356
7. Journal / agency Goa KL, Brogden RN. Propiram. A review of its pharmacodynamic and pharmacokinetic properties, and clinical use as an analgesic. Drugs. September 1993. doi:10.2165/00003495-199346030-00008 · PMID 7693433

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0), PubChem (public domain). Each value links to the exact revision it came from.